Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV)-associated lymphoepithelioma. The aim of this study was to characterize the homogeneity and distinctness of the T-cell repertoires within and between primary and metastatic NPCs. We used ultra-deep sequencing of the hypervariably rearranged antigen-binding CDR3 regions of T-cell receptor beta (TCR beta ) to comprehensively profile the T-cell repertoires in NPC patients receiving definitive chemoradiotherapy with long-term follow-up. We observed not only various spatially heterogeneous patient-specific TCR beta clone compositions that changed with time but also several commonly enriched TCR beta subclones that were constantly shared between primary NPCs in the head and neck regions, locally recurrent tumors after treatment and later-developed distant metastatic tumors in the liver, lung and bone.
B-lymphocytes to generate diverse repertoires of antigen receptors through the recombination of variable (V), diversity (D) and joining (J) gene segments at antigen receptor loci. 7, 8 More functional diversity of T-cell receptors (TCRs) is further generated by the insertion and/or deletion of nucleotides during the somatic V-D-J recombination to create highly variable complementarity determining regions (CDRs). [9] [10] [11] The overall rearranged diversity, extent of sequence variability and total number of different subtypes of TCRs form an immune repertoire, which could be regarded as a recording of viral and environmental exposure, a defensive system against infection and tumorigenesis, and a connection between health and disease. The TCR on the T-lymphocytes is a disulfide-linked membrane-anchored heterodimeric protein normally consisting of highly variable alpha and beta chains (TCR 2) (95%) or gamma and delta chains (TCR 1) (5%), structurally similar to the light and heavy chains of immunoglobulins (antibodies) secreted by B lymphocytes. 12 Previous studies have shown that T lymphocytes constitute 80% of tumor-infiltrating lymphocytes (TILs), and, among them, CD8
1 cytotoxic lymphocytes are the major effectors of adaptive immunity. 13 The antigen contact region of the TCRbeta chain (TCR beta ), called CDR3, showing the greatest variability, is responsible for recognizing antigens bound to major histocompatibility complex (MHC) molecules and determines the antigen-binding specificity.
Because the composition of the immune repertoire could be dynamic over time and is affected by disease progression and treatment, the sequencing of the TCR beta CDR3 of TILs that recognize neoantigen and/or viral antigens has emerged as a promising approach to detect the clonal evolution of virus-related oncogenesis and correlate with the clinical prognosis after treatment. 14 Identifying the NPC-shared T-cell subclones and common productive antigen-binding CDR3 amino acid sequences within primary and metastatic tumors may trace back to identify the currently unknown viral-or non-viral-associated neoantigens of NPC cells, provide prognostic biomarkers, and form a basis for the design of specific immunotherapy.
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Materials and Methods
Patients and samples
After institutional review board approval, we analyzed 84 biopsy-proven EBV-positive NPC patients with no known bone and/or visceral metastasis at initial diagnosis between 2007 and 2009. They were all treated with definitive cisplatin-based chemoradiotherapy of 70 Gy in 35 fractions over 7 weeks. The median follow-up time was 76.6 months (range, 60.3-94.8 months). Twelve of the patients developed local recurrence and/or distant metastasis after chemoradiotherapy and received further biopsy and/or metastasectomy. The biopsied and resected tumors were formalin fixed, dehydrated and embedded in paraffin. All patients provided written informed consent for biopsy, pathology analysis and treatment.
Pathology correlation
Histology. Deparaffinized sections (4 mm) were treated with 1% H 2 O 2 to block endogenous peroxidase activity and were immersed in boiling 0.01% citric acid (pH 6.0) in a microwave oven for 15 min to enhance antigen retrieval. After cooling, the sections were rehydrated with PBS and stained with hematoxylin and eosin (H&E).
In situ EBV hybridization. Tissue sections (4 lm) from the paraffin blocks were deparaffinized, rehydrated with PBS, digested with pepsin (30 lg/mL) for 10 min at 378C, fixed in 4% paraformaldehyde in PBS, and washed in 33 saline solution citrate (SSC) buffer (0.15 M sodium chloride, 15 mM sodium citrate, pH 7.0). A probe representing the EBV component, EBER-1, was labeled with digoxigenin-dUTP by random priming using the DNA labeling kit (Boehringer Mannhim). The samples were prehybridized at 408C for 2 hr, and hybridization was performed overnight at 408C using the EBV probe. After hybridization, excess probe was removed by sequential washing in 23 SSC, 0.53 SSC and then 0.23 SSC at 378C for 2 hr. The tissue sections were incubated at 378C for 1 hr with biotinylated mouse anti-digoxigenin, followed by the addition of streptavidin-biotin-peroxidase complex for 20 min and a 5-min incubation with 3,3 0 -diaminobenzidine/hydrogen peroxide as the substrate chromogen (Dako).
Immunohistochemistry. After deparaffinization, the tissue sections (4 mm) were pretreated for 25 min in a Sharp TM microwave oven (988C) for heat-induced epitope retrieval at pH 6.0 (TRIS-EDTA-buffer). Standard indirect immunoperoxidase procedures were used for the visualization of What's new? Epstein-Barr virus-associated nasopharyngeal carcinoma (NPC) shows marked infiltration of T lymphocytes around and within the tumors, but the relevance of this infiltration to disease outcome is not clear. Here the authors profiled the T-cell receptor b-chain (TCRbeta) repertoires from different patients with NPCs and show that their phylogeny clearly differentiated low-risk patients without relapse from high-risk metastatic patients. The authors propose that the persistent presence of the TCRbeta subclones found in primary and later-developed metastatic tumors may be exploited for adoptive immunotherapy to improve disease outcome for patients with distant metastases.
bound primary antibody (cytokeratin, CK AE1/AE3) (Dako). Diaminobenzidine was used as the chromogen.
DNA extraction and high-throughput TCR beta sequencing DNA was extracted from the formalin-fixed, paraffin-embedded specimens using the DNA mini kit from Qiagen following the manufacturer's instructions. To generate the template library for analysis of the TCR beta immune repertoire, a multiplex PCR-based next-generation sequencing system was designed to amplify millions of rearranged TCRbeta CDR3 regions from genomic DNA. As described previously, [18] [19] [20] 45 forward primers (each specific to a functional TCR Vb segment) and 13 reverse primers (each specific to a TCR Jb segment) were used. The selected primer sets only amplified the recombined V-D-J area. The forward and reverse primers contained an adaptor at their 5 0 ends. The Illumina GA2 System generated reads of length that covered the entire range of TCR beta CDR3 lengths.
Construction of phylogeny using TCR beta CDR3 sequence variance
To evaluate the extent of close and remote relationships between tumors and patients, we generated an overlap metric of TCR beta repertoires as described previously. 21 Briefly, the TCR beta overlap between samples was defined as the total number of sequencing read counts from shared TCR beta CDR3 sequences [R(the shared clone between the sample multiplied by its number of reads)] divided by the sum of sequencing read counts detected in both samples [R(each clone of the two samples multiplied by its number of reads)]; the value range is 0-1. Next, the TCR beta overlap was converted into a distance metric by computing [(1/TCR beta overlap) 2 1)], the value range is 0-1; the higher value indicates far fewer related TCR beta repertoires. Based on the genetic distance, we constructed a nearest-neighbor phylogenetic tree to find the same clustering defined by Ward's method. 22 
Results
Assessment of the TCR beta repertoires in EBV-associated lymphoepithelioma of the nasopharynx, NPC
In line with previous findings of infrequent genomic mutations but widespread methylation in the mutational landscape of EBV-associated NPC, [23] [24] [25] [26] our whole-exome sequencing approach also detected a very low frequency of nonsilent somatic mutations in only 7 (8.3%) of the pretreatment nasopharyngeal biopsy specimens of the 84 staged EBV-associated NPC patients who had at least 5-year follow-up after definitive chemoradiotherapy ( Supporting Information, Fig. S1 ). Because the nasopharynx posterior to the nasal cavity is part of the Waldeyer's ring of lymphatic tissues in the head and neck, the marked infiltration of lymphocytes around and within EBV-related NPC as a lymphoepithelioma might reflect mixed reactive responses to not only individual circumstances of infection, inflammation and allergy but also the epigenetic interactions of host genetics and EBV infection. As opposed to the rare events of tumor genomic mutations in the evolution of EBV-associated NPC cells, the immense variation of NPC-infiltrating lymphocyte receptor repertoire structures (clonal richness and evenness) and clonotyping (sequence variance), which reflect the state of clonal selection and expansion throughout oncogenesis and the lifetime of an individual, might serve as a fingerprint of an individual's ongoing immunological status in reaction to environmental exposure, pathogenic antigen challenge and epigenetic alterations (Fig. 1) . Thus, to explore the tumor immune microenvironment, we then determined the differential extent of clonal diversity (richness), distribution (evenness) and TCR beta repertoire receptor overlapping in the 84 NPC patients, and asked if there were shared neoantigens shaping NPC-specific T-cell repertoires.
We profiled the rearranged DNA sequences spanning the antigen-binding sites of TCR beta CDR3 of the T cells in NPCs in the 84 patients. Notable repertoire skewing was observed (Fig. 2a) . The most frequent TRBV, TRBD and TRBJ gene segment usages for TCR beta V-D-J CDR3 gene recombination were TRBV6-1, TRBD1 and TRBJ2-3, respectively. Remarkable diversity of the TCR beta repertoires and polyclonality was identified with 302,452 in-frame CDR3 amino acid clonotypes (Supporting Information, Table S1 ). The number of clonotypes did not correlate with the size and stage of tumors (Fig. 2b) . The unique or private sequences (93.86%) only seen in one patient could be regarded as patient specific; the common or shared sequences (6.14%) repeatedly uncovered in different NPCs could be potentially tumor shared (Supporting Information, Table S2 ). The 247 most commonly tumor-shared productive CDR3 clones detected in at least 10% of the patients were 7-22 amino acids in length, among which 54 clones appeared recurrently in at least 20% of the patients (Fig. 2c) .
We next compared the 302,452 in-frame TCR beta CDR3 amino acid sequences from the EBV-associated NPC-infiltrating lymphocytes against the public database sequences. [27] [28] [29] Only 18 of the sequences were found to have identical matches to the known CD8 1 T-cell clones corresponding to EBV infection and were specific for the epitopes of BZLF1 or BMLF1 of the EBV lytic proteins in 32 patients (38%) ( Table 1) . As expected, we also found the T-cell clonotypes expanding secondary to other viral infections such as influenza-A, cytomegalovirus, human immunodeficiency virus, hepatitis C virus and yellow fever virus in 58 patients (69%) (Supporting Information, Table S3 ). Moreover, 10 TCR beta clones responding to the known neoantigens of bone marrow stromal antigen 2 (BST2), melanoma antigen recognized by T cells 1 (MLANA) or transketolase (TKT) were identified in 20 patients (24%) ( Table 1) . [30] [31] [32] However, most of the CDR3 sequences from the TILs of NPCs were not discovered in the public databases, suggesting our tumor-shared clonotype dataset might likely include NPC-exclusive clonality. Comparison of the TCR beta repertoires in NPC patients with or without distant metastasis after chemoradiotherapy Both oligoclonal and polyclonal TCR beta repertoires were noted in the NPC-infiltrating lymphocytes (Fig. 3a) . We then examined if the immune receptor clonal diversity (richness) and distribution (evenness) could define subgroups associated with overall outcomes in NPC patients after chemoradiotherapy. However, we found that the Hill-based diversity (richness) and distribution (evenness) profiles did not cluster TCR beta repertoires of disease-free, locally recurrent and distantly metastatic patients well (Supporting Information, Fig. S2 ). 33 Thus, in contrast to sequence-independent clonal structure diversity profiling, we further queried if CDR3 amino acid sequence variance (clonotyping) could reveal biologically distinct subsets of NPC.
Based on the homogeneity (tumor-shared in-frame CDR3 amino acid sequences), distinctness (patient-specific in-frame CDR3 amino acid sequences) and different clone frequencies shown in the TCR beta repertoires among NPC patients, to assess the similarity and difference, we then used a clustering metric to demonstrate the extent of overlap of TCR beta repertoires among patients (Fig. 3b) . After the pairwise overlap metric was converted to a dendrogram through a genetic distance measure based on an agglomerative hierarchical cluster analysis, the Ward's method, NPC patients with or without distant metastasis after treatment were clustered into two separate groups in general (Fig. 3c) . In the neighbor-joining phylogeny tree showing close and remote relationships, the NPC patients without relapse >7 years after treatment were grouped by genetic distance in the range of 3.3-15.6; on the other hand, the NPC patients with distant metastasis within 3 years after treatment were grouped by genetic distance in the range of 1.2-4.2. By contrast, the two opposite risk groups with clinically outmost contrary outcomes displayed relatively much longer pairwise distance metrics from 33.0 to 247,023.5, suggesting that far-fewer related TCR beta repertoires exist between the NPC patients without relapse and the NPC patients with distant metastasis.
For cross-validation, a phylogenetic tree of the NPCinfiltrating TCR beta repertoires was also reconstructed using the single linkage method. 34 The tree topology clearly demonstrated that the NPC patients were classified into distinct categories with or without local recurrence or distant metastasis ( Supporting Information, Fig. S3a) . Moreover, based on the pairwise genetic distance matrix (Fig. 3b) , a 3-D representation obtained by the principal component analysis also exhibited separate clusters corresponding to patients with free of disease, local recurrence and distant metastasis, which was in line with the hierarchical clustering by the single linkage and Ward's methods (Fig. 3c and Supporting Information,  Fig. S3b) . 35 Taken together, our results indicated that the immune-repertoire-based clonotyping (CDR3 sequence variance), but not clonal structure diversity (richness and evenness), correlated with prognosis and could predict the risk of NPC after treatment.
Spatial and temporal relationships among TCR beta repertoires between primary NPCs and their local relapses or distant metastases
To evaluate the dynamics of the TCR beta repertoire over time, we investigated the similarity and difference between a series of repeated nasopharyngeal biopsy samples from three patients with local recurrence 5 years after chemoradiotherapy (Fig. 4a) . To reduce the rare clone sampling bias, 21 we assessed the spatiotemporal clonal composition of the NPCinfiltrating lymphocytes, including only the top 100 T-cell clones detected with the highest frequency in each sample (Supporting Information, Table S4 ). The overall TCR beta repertoire overlap rates were stable at 22.7-23.3% without marked fluctuation between primary tumors before treatment, nasopharyngeal mucosa after treatment and-laterlocally recurrent tumors. Namely, the temporal genetic distance appeared to be constantly short 3.3-3.7 at different time points. However, only 24.4-31.7% of the tumor-shared T-cell clonotypes discovered in the primary NPCs were found within recurrent NPCs, suggestive of the presence of both probable clonal drifts and subclone persistence with time after treatment.
Next, to assess the spatial distribution and location of the tumor-shared T-cell populations in NPCs, we compared the TCR beta repertoires within different compartments at the primary tumor core, at the peripheral edge of the primary tumors, ipsilateral tonsil of the same Waldeyer's ring, and lowest metastatic neck lymph nodes in three patients (Fig.  4b) . We observed that despite various frequencies of at least 4.6-8.1% of the tumor-shared T-cell clonotypes discovered in the main part of the primary NPCs, they could be found in the remote borders of each tumor. The overlap extent of TCR beta repertoires between different marginal sites of the same tumor was similar to 15.2-17.5%, which were translated to 4.6-5.6 of spatial genetic distance. The presence of shared TCR beta clones among different portions of the same patient revealed a degree of spatial homogeneity. However, the spatial genetic distance between the primary tumor center and peripheral tumor site within a single tumor appeared to be longer than the temporal genetic distance between the primary NPCs and their later recurrent in situ tumors (Figs. 4a  and 4b) . The results might reflect spatial microenvironment difference and intratumor heterogeneity.
Because the commonly expanded T-cell clones present in the primary NPCs could be reactive to the same non-tumorassociated antigens exclusively located in the nasopharyngeal environment, we subsequently inspected whether the NPCspecific TCR beta repertoires were also sustained spatiotemporally in the distant metastatic tumors in the twelve patients who developed metastasis to the liver, lung or bone 2-5 years after treatment (Fig. 4c) . The physiological environment of the liver, lung and bone is completely different from that of the nasopharynx and can induce diverse T-cell clonal expansion not associated with NPC and EBV. We found that, although previous chemoradiotherapy might further alter tumor-associated antigens, modify immune responses and/or deplete immune cells, 8.5-11.8% of the primary NPC-shared T-cell clonotypes were identified within the distant metastatic tumors with low-to-high frequencies in all the 12 patients. In combination with the tumor-shared and organ-specific clonotypes with their frequencies, the TCR beta overlap rates and genetic distance between the initial primary NPCs and the subsequently developed distant metastatic tumors in the same patient after chemoradiotherapy were still up to 17.5-45.5% and close to 1.2-4.7, respectively, in contrast to the relatively long genetic distance from 27.4 to 32,518.6 between different NPCs. Our results demonstrated that a few common subsets of T-cell clones of TILs found in primary NPCs were persistently juxtaposed to distant metastatic NPC cells regardless of anatomic location, physiological microenvironment and developmental time of metastasis (Table 2 ) and were not matched to any known T-cell clones specific to EBV, other viruses or neoantigens in the public databases despite the persistent presence of EBV in metastatic epithelial cancer cells.
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Discussion
NPC arising from the superior aspect of the pharyngeal mucosal space is a unique lymphoepithelioma that includes a mosaic pattern of benign lymphoid cells and malignant epithelial carcinoma cells, associated with latent EBV infection in most cases. In our study, the dense tumor-infiltrating Tcell populations in NPCs were initially found to be spatially heterogeneous, and their dominant clonal constitution tended to change dynamically. However, for the first time, we reveal that there are tumor-shared T-cell subclones displaying common antigen-binding CDR3 clonality in a certain fraction of the TCR beta repertoires among many NPC patients, and persistently exist in the distant organ metastases in the liver, lung and bone over time.
We found a relatively high degree of overlap of the intratumor productive TCR beta repertoires between primary NPCs and their later-developed distant metastatic tumors after chemoradiotherapy. The finding of NPC-shared tumor-infiltrating T-cell populations across different patients and distinct organs with time implied the existence of specific T-cell immune responses to certain common neoantigens presenting on NPC cells. Thus, our in-frame antigen-binding CDR3 amino acid sequences derived from the comprehensive nextgeneration sequencing of the NPC-specific TCR beta clonotypes might reflect or mirror the epitope spectrum of neoantigens of NPCs. Moreover, the overlap extent of the hypervariable CDR3 domains of the TCR beta repertoires enabled us to construct an NPC phylogeny. We found a split in the T-cell phylogenetic tree bipartitioning the NPC patients into two groups correlated without relapse and with distant metastasis after treatment, respectively, indicating that differential immune responses and host immunity to NPCs could be highly associated with prognosis in NPC patients. In contrast to the genomic mutation landscape in the epithelial cancer part that did not correlate with tumor evolution and clinical outcomes, 23 the profiling of TCR beta antigenbinding CDR3 subclones of the TCR repertoires in the NPCinfiltrating lymphocytes seemed to divulge the patient's prognosis. Thus, although interactions between immune and malignant cells have been known to show clinical relevance for decades in other cancers, 36 this study first provides a missing link between tumor immunity and disease outcome in EBV-associated lymphoepithelioma of the nasopharynx.
However, we did not know whether the NPC-specific TILs found within the metastases moved together with the interacting cognate primary epithelial carcinoma cells from the nasopharynx or were later attracted or recruited to the distant organs to cooperate with the metastatic epithelial carcinoma cells that expressed NPC-specific antigens. Because EBV was not lost in the metastases, we also did not know whether the NPC-specific TILs were attracted by virusexpressing processed antigens or non-virus-associated neoantigens of NPCs. Although EBV infection should produce viral proteins that-on the face of the infected cellsare ideal targets for robust immune elimination, EBV has developed several strategies to impair the antigen-processing and major histocompatibility complex (MHC)-presenting machinery in EBV-containing cells for immune evasion. [37] [38] [39] On the other hand, previously detailed genomic landscape analyses of NPCs have shown that, compared with other virally associated cancers, such as EBV-positive gastric adenocarcinomas and human papillomavirus-positive oropharyngeal squamous cell carcinomas, the mutation frequency of NPC of 1-342 coding mutations/patient is relatively low. 23, 39, 40 Even the most widely mutated TP53 in human cancers is only mutated in 0-8% of the NPC patients. 41 The low mutation burdens in NPCs may limit the creation of somatically mutated cancer antigens, resulting in a paucity of neoantigens displayed on the surface of cancer cells and less intrinsic immunogenicity. Thus, to explore the relative contribution of viral, tumor or host MHC factors to the generation of tumor-associated antigens affecting immune responses to the EBV-associated NPC, the overlap degrees and genetic distance of TCR beta repertoires of the tumor-infiltrating lymphocytes between EBV-positive and EBV-negative NPCs, and between EBV-associated NPCs and EBV-associated gastric cancers, need to be compared. 41 Because TCR protein is a heterodimer composed of an a chain and a b chain, to clone the intact TCRs specific for various tumor-associated antigens, further studies are required to identify the matching TCR alpha to pair with the tumor-shared TCR beta CDR3 domains. 42 The sequences of TCR alpha-beta pairs of individual T cells can be used to pull out their corresponding virally and/or nonvirally target epitopes and the coupled MHC. Functional studies are warranted to confirm whether these NPC-specific T-cell clones or subtypes can be activated by EBV or tumor antigens and have biological relevance in relation to the response of chemoradiotherapy.
In conclusion, in addition to having a prognostic value, the presence of the commonly expanded TCR beta CDR3 subclone composition in all the primary and metastatic EBVassociated NPCs provides evidence of using immune checkpoint inhibitors to unleash the antitumor activity of NPCinfiltrating T-cell lymphocytes, 43 and opens opportunities to engineer chimeric antigen receptor T cells for adoptive transfer to treat stage IV NPC patients with distant metastasis. 
